A rare, mutated version of a protein called TNIP1 has been discovered that causes a chronic autoimmune disease similar to Sjogren’s Syndrome – a condition that leads to extreme dryness of the eyes and mouth that can cause blindness if left untreated. The discovery could lead to new treatments.
The new study has revealed that the TNIP1 mutation may also be responsible for more severe autoimmune diseases including lupus.
The researchers say they were able to successfully reverse the damaging effects of the mutation in mice, bringing them a step closer to developing new drug therapies that do the same in humans.
The findings could lead to new and tailored treatments for Sjogren’s Syndrome and lupus that is caused by TNIP1 variants.
Lead author Dr Arti Medhavy, who completed this work as part of her PhD at The Australian National University (ANU), said this is the first time scientists have shown a variation of the TNIP1 protein is responsible for causing autoimmune disease in humans.
“Proteins are critical to our growth, development and overall health, but they have a shelf life. Once the proteins have served their purpose, they become deactivated,” said Dr Medhavy.
“That’s where TNIP1 comes in. It works in unison with the cell’s waste management system. TNIP1 essentially acts as a gatekeeper of the immune system by removing obsolete proteins and taking them to the cell’s degradation sites where they are broken down, recycled and repurposed.
“Genetic material is normally packaged within specific compartments of the cell, including the cell’s energy factories which are called mitochondria. The same genetic material, however, can trigger alarms in the immune system if detected outside of these specialised compartments.
“Importantly, TNIP1’s role in the waste management system includes the removal of damaged or leaky mitochondria, which helps maintain healthy cells.
“But the mutated version of the TNIP1 protein is less efficient at taking these waste proteins and mitochondria to be processed, leading to toxic build-up within cells. If this waste isn’t dealt with, these materials can become detrimental to the cell and trigger the immune system, which ultimately promotes the onset of autoimmune disease.”
Developing new treatments
Study co-author Dr Vicki Athanasopoulos, from ANU, has said that there is a need to develop tailored treatments that specifically target the proteins and biochemical pathways that lead to the onset of autoimmune disease, rather than suppressing the entire immune system.
“There is currently no cure for autoimmune disease. Current therapies help patients better manage their condition, but these treatments have unpleasant side effects that make patients more susceptible to infection, which can lower their quality of life,” Dr Athanasopoulos said.
The researchers identified the TNIP1 mutation in two unrelated patients – one from Australia and the other from China. Despite both having the same TNIP1 mutation, one patient exhibited signs and symptoms of lupus, while the other seemed to possess symptoms of Sjogren’s Syndrome.
Gene technology
Using gene-editing technology, the researchers introduced the human equivalent TNIP1 mutation into mice and found that mice carrying the mutation developed a condition that mimicked the Sjogren’s disease-like symptoms seen in one of the human patients.
“The TNIP1 mutant protein is similar to the lupus-causing TLR7 mutation in that it affects the same biochemical pathway. There is work already underway by pharmaceutical companies to develop new drugs and tweak existing ones that inhibit the TLR7 pathway,” Dr Athanasopoulos said.
According to Dr Medhavy, although both patients with the TNIP1 mutation had slightly different forms of autoimmune disease, they both had abnormally high levels of IgG4 antibodies in their blood.
“The abnormally high presence of IgG4 in both patients is interesting because clinicians might be able to use IgG4 as a biomarker of TNIP1-driven autoimmune disease,” she said.
“By screening patients with autoimmune disease for high levels of igG4, clinicians might be able to test whether patients also possess the TNIP1 mutation, which would indicate that they may respond well to therapies targeting the same TLR7-pathway.”
The research is published in Nature Immunology. This work also involved scientists from the Francis Crick Institute in the UK and Shanghai Jiao Tong University in China.
